-
Created
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added
nejmoa2102137.pdf
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator W. Schuyler Jones
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Hillary Mulder
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Lisa M. Wruck
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Michael J. Pencina
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Sunil Kripalani
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Daniel Muñoz
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator David L. Crenshaw
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Mark B. Effron
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Richard N. Re
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Kamal Gupta
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator R. David Anderson
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Carl J. Pepine
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Eileen M. Handberg
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Brittney R. Manning
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Sandeep K. Jain
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Saket Girotra
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Danielle Riley
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Darren A. DeWalt
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Jeff Whittle
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Ythan H. Goldberg
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Veronique L. Roger
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Rachel Hess
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Catherine P. Benziger
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Peter Farrehi
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Li Zhou
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Daniel E. Ford
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Kevin Haynes
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Jeffrey J. VanWormer
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Kirk U. Knowlton
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Jennifer L. Kraschnewski
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Tamar S. Polonsky
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Dan J. Fintel
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Faraz S. Ahmad
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator James C. McClay
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator James R. Campbell
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Douglas S. Bell
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Gregg C. Fonarow
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Steven M. Bradley
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Anuradha Paranjape
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Matthew T. Roe
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Holly R. Robertson
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Lesley H. Curtis
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Amber G. Sharlow
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Lisa G. Berdan
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Bradley G. Hammill
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Debra F. Harris
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Laura G. Qualls
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Guillaume Marquis-Gravel
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Madelaine F. Modrow
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Gregory M. Marcus
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Thomas W. Carton
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Elizabeth Nauman
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Lemuel R. Waitman
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Abel N. Kho
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Elizabeth A. Shenkman
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Kathleen M. McTigue
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Rainu Kaushal
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Frederick A. Masoudi
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Elliott M. Antman
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Desiree R. Davidson
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Kevin Edgley
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator James G. Merritt
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Linda S. Brown
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Doris N. Zemon
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Thomas E. McCormick
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Jacqueline D. Alikhaani
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Kenneth C. Gregoire
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Russell L. Rothman
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Robert A. Harrington
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Adrian F. Hernandez
February 17, 2023 11:52
by
Researcher Metadata Database
-
Added Creator Oana A. Sandu
February 17, 2023 11:52
by
Researcher Metadata Database
-
Published
February 17, 2023 11:52
by
Researcher Metadata Database
-
May 27, 2023 13:09
by
avs5190
Description
<p>The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy. METHODS Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis. The primary safety outcome was hospitalization for major bleeding, also assessed in a time-to-event analysis. RESULTS A total of 15,076 patients were followed for a median of 26.2 months (interquartile range [IQR], 19.0 to 34.9). Before randomization, 13,537 (96.0% of those with available information on previous aspirin use) were already taking aspirin, and 85.3% of these patients were previously taking 81 mg of daily aspirin. Death, hospitalization for myocardial infarction, or hospitalization for stroke occurred in 590 patients (estimated percentage, 7.28%) in the 81-mg group and 569 patients (estimated percentage, 7.51%) in the 325-mg group (hazard ratio, 1.02; 95% confidence interval [CI], 0.91 to 1.14). Hospitalization for major bleeding occurred in 53 patients (estimated percentage, 0.63%) in the 81-mg group and 44 patients (estimated percentage, 0.60%) in the 325-mg group (hazard ratio, 1.18; 95% CI, 0.79 to 1.77). Patients assigned to 325 mg had a higher incidence of dose switching than those assigned to 81 mg (41.6% vs. 7.1%) and fewer median days of exposure to the assigned dose (434 days [IQR, 139 to 737] vs. 650 days [IQR, 415 to 922]). CONCLUSIONS In this pragmatic trial involving patients with established cardiovascular disease, there was substantial dose switching to 81 mg of daily aspirin and no significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg and those assigned to 325 mg of aspirin daily.</p>
- <p>BACKGROUND The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy. METHODS Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis. The primary safety outcome was hospitalization for major bleeding, also assessed in a time-to-event analysis. RESULTS A total of 15,076 patients were followed for a median of 26.2 months (interquartile range [IQR], 19.0 to 34.9). Before randomization, 13,537 (96.0% of those with available information on previous aspirin use) were already taking aspirin, and 85.3% of these patients were previously taking 81 mg of daily aspirin. Death, hospitalization for myocardial infarction, or hospitalization for stroke occurred in 590 patients (estimated percentage, 7.28%) in the 81-mg group and 569 patients (estimated percentage, 7.51%) in the 325-mg group (hazard ratio, 1.02; 95% confidence interval [CI], 0.91 to 1.14). Hospitalization for major bleeding occurred in 53 patients (estimated percentage, 0.63%) in the 81-mg group and 44 patients (estimated percentage, 0.60%) in the 325-mg group (hazard ratio, 1.18; 95% CI, 0.79 to 1.77). Patients assigned to 325 mg had a higher incidence of dose switching than those assigned to 81 mg (41.6% vs. 7.1%) and fewer median days of exposure to the assigned dose (434 days [IQR, 139 to 737] vs. 650 days [IQR, 415 to 922]). CONCLUSIONS In this pragmatic trial involving patients with established cardiovascular disease, there was substantial dose switching to 81 mg of daily aspirin and no significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg and those assigned to 325 mg of aspirin daily.</p>
-
Deleted Creator Oana A. Sandu
May 27, 2023 13:09
by
avs5190
-
Updated
April 04, 2024 10:22
by
[unknown user]